What Is the Bolar Exemption in Germany in 2026, API Suppliers, Cmos/cros & Section 11 Patg Explained

The Bolar exemption is a statutory patent-law defence that permits the use of a patented invention, without the patent holder’s consent, for the specific purpose of generating data required to obtain a marketing authorisation (MA) for a generic or biosimilar medicine. In Germany, this exemption is codified in Section 11 of the Patent Act (Patentgesetz, PatG), and the 2026 EU Pharma Package has brought renewed attention to its scope, particularly for third-party actors in the pharmaceutical supply chain.

For in-house counsel at generics companies, contract manufacturers (CMOs), contract research organisations (CROs) and active pharmaceutical ingredient (API) suppliers, understanding the Bolar provisions in Germany is no longer optional, it is a front-line compliance obligation that directly affects operational freedom, contracting strategy and litigation exposure.

What Is the Bolar Exemption and Why Does 2026 Matter?

At its core, the Bolar exemption answers a practical problem: generic and biosimilar applicants need to conduct studies and manufacture test batches before a patent or supplementary protection certificate (SPC) expires so that they can file for regulatory approval and launch promptly once exclusivity ends. Without a Bolar-type defence, these preparatory activities would constitute patent infringement.

The exemption takes its name from the landmark 1984 US case Roche Products v. Bolar Pharmaceutical and its subsequent codification in the Hatch-Waxman Act. In the European Union, the legal basis sits in Article 10(6) of Directive 2001/83/EC, which was transposed into German law through Section 11 PatG. The 2026 EU Pharma Package, formally adopted to modernise the pharmaceutical regulatory framework, has clarified and, in important respects, harmonised Bolar provisions across Member States, particularly regarding third-party involvement in MA-related activities.

Industry observers expect the practical effect of the EU Pharma Package Bolar changes to be a more uniform interpretation of which supply-chain participants can rely on the exemption, though the German courts will ultimately shape the boundaries of that interpretation under Section 11 PatG.

Legal Basis in Germany: Section 11 of the Patent Act (PatG)

Section 11 PatG sets out the exceptions to the effects of a patent. The provision most relevant to pharmaceutical manufacturers and their contractors is Section 11(2) PatG, which stipulates that the effects of a patent shall not extend to studies and trials, and the practical requirements thereof, that are necessary for obtaining a marketing authorisation for medicinal products.

The statutory text is deliberately broad in its reference to “studies and trials, and the practical requirements thereof” (Studien und Versuche und die hierfür erforderlichen praktischen Anforderungen). German courts, and the Düsseldorf Regional Court (Landgericht Düsseldorf) in particular, as Germany’s most active patent litigation forum, have interpreted this language to encompass a range of preparatory activities: bioequivalence studies, stability testing, process validation and the manufacture of clinical trial batches, provided they serve the sole purpose of regulatory approval.

The critical link to EU law is Article 10(6) of Directive 2001/83/EC, which provides the harmonised baseline for the Bolar exemption across all Member States. The 2026 EU Pharma Package builds on this by seeking to ensure that the exemption is interpreted consistently, including in situations where multiple parties (such as CMOs, CROs or API suppliers) participate in the MA-related supply chain on behalf of the applicant. For Germany, this means that the established interpretation under Section 11 PatG must now be read in light of the EU-level clarifications, a development that is particularly significant for the German pharmaceutical market, where generics account for a substantial share of prescription volumes.

A key nuance in the German legal landscape is the distinction between the Bolar exemption and the broader research exception in Germany (also found in Section 11 PatG). The research exception covers purely experimental or scientific activities aimed at investigating the patented subject matter itself. The Bolar provision, by contrast, is narrower in purpose, it protects activities undertaken specifically “for” obtaining regulatory approval, but broader in the type of work it shields (manufacturing, import of samples, clinical trials). Practitioners must not conflate the two, as relying on the wrong exception can defeat a defence entirely.

Who Is Covered Under the Bolar Exemption in Germany (2026 Interpretation)?

The most contested question in German Bolar practice is whether the exemption extends beyond the MA applicant to third parties acting on its behalf. The 2026 EU Pharma Package has brought this issue into sharper focus, but significant ambiguity remains under domestic case law.

Direct Applicants and MA Holders

The generic or biosimilar company that is itself applying for, or intends to apply for, a marketing authorisation is the undisputed primary beneficiary of the Bolar exemption. This entity may conduct bioanalytical studies, regulatory testing, process development, stability studies and clinical trials using the patented compound without incurring patent infringement liability, provided the activities are genuinely and exclusively linked to the MA application. Documentary proof of the MA-related purpose (project timelines, regulatory submissions, correspondence with authorities) is essential.

Contract Manufacturers (CMOs) and the Bolar Exemption

Whether a contract manufacturer, producing test batches, validation lots or clinical trial material on behalf of the MA applicant, can independently invoke the Bolar exemption is an area of active legal debate in Germany. Some German courts have indicated that the exemption is personal to the entity with a direct interest in obtaining the MA, which would leave CMOs exposed to infringement claims even when their manufacturing activity is functionally identical to work the applicant could perform in-house. Other jurisdictions within the EU, and academic commentary in GRUR International, have adopted a more functional reading: if the activity is carried out “for” the purpose of regulatory approval, the identity of the actor performing it should not matter.

The EU Pharma Package Bolar clarifications are expected to support this functional interpretation, though German courts have not yet fully aligned their case law with the updated EU position.

API Suppliers and Subcontractors

The position of third-party API suppliers is even more uncertain. Scholarly analysis, notably from the Max-Planck Institute for Innovation and Competition, has explored whether the supply of a patented API to a generic applicant or its CMO falls within the scope of the Bolar exemption when the API is destined exclusively for MA-related manufacture. The prevailing academic view is that functional coverage is arguable but far from settled, and recent commentary has noted that some national courts have rejected Bolar protection for subcontractors operating at arm’s length from the MA applicant. API suppliers face the highest residual risk in the supply chain and should implement strict contractual and documentary controls.

Clinical Trials, Regulatory Data and Experimental Use: What Is Allowed?

The clinical trial exemption in Germany is closely related to, but not identical with, the Bolar exemption. Understanding where these provisions overlap and diverge is critical for CROs, sponsors and their legal advisers.

Clinical Trial Conduct Versus MAA Support

Activities that fall squarely within the Bolar exemption include Phase I–III clinical trials conducted to generate data for a marketing authorisation application, bioequivalence studies for generic medicines, and comparability studies for biosimilars. The exemption covers not only the conduct of the trials themselves but also the “practical requirements thereof”, meaning the manufacture, import and supply of clinical trial material using the patented compound. The key condition is that the trial must serve the regulatory approval objective. Trials conducted for purely commercial purposes (for example, to generate data for marketing claims post-launch, or investigator-initiated studies unrelated to an MA dossier) fall outside the scope of the Bolar provisions in Germany.

Clinical Trial Data and Data Exclusivity

A related but distinct issue is data exclusivity, the period during which an MA applicant cannot cross-refer to the originator’s clinical trial data to support its own application. Data exclusivity is a regulatory concept (governed by the EU Pharma Package and Directive 2001/83/EC), not a patent-law concept. The Bolar exemption permits the generation of data through studies and trials; it does not override data-exclusivity or regulatory-data-protection periods. Practitioners should note the red flag: even where Bolar shields the physical conduct of a trial, the resulting data may not be usable to support an MA filing until the relevant data-exclusivity period expires.

This distinction, between what may lawfully be done and what may lawfully be submitted, is a frequent source of confusion and must be addressed in project planning.

Supply Chain Focus: API Manufacturing, Intermediates and Import/Export Risks Under the Bolar Exemption

API manufacturing and supply sit at the junction of patent risk and regulatory necessity. The question of whether the supply of a patented API constitutes a protected Bolar activity or an infringing commercial act is among the most practically significant, and least settled, issues in German pharmaceutical patent law.

When API Supply Is Covered

Where an API supplier manufactures and delivers a patented active substance to a generic applicant (or its CMO) exclusively for the purpose of producing test batches, stability samples, or clinical trial material destined for inclusion in an MA dossier, there is a credible argument that the activity is functionally within the Bolar exemption. This argument is strongest when the supplier can demonstrate: (a) a written contract limiting the purpose of the supply to MA-related activities; (b) batch-level traceability linking each delivery to a specific regulatory project; and (c) quantities consistent with regulatory (not commercial) requirements.

Conversely, if API volumes exceed what is needed for regulatory purposes, or if the API is stockpiled for commercial launch, the Bolar defence will almost certainly fail.

Practical Controls for API Suppliers

Given the legal uncertainty, API suppliers operating in the German market should implement the following controls:

• Written purpose-limitation clauses. Every supply agreement must expressly restrict use of the API to activities covered by the Bolar exemption and prohibit commercial exploitation before patent/SPC expiry.
• Batch and project-code traceability. Each shipment should be linked to a specific MA project number, with records retained for the duration of any patent or SPC term.
• Quantity caps. Contractual and operational limits on volumes supplied, calibrated to what is demonstrably necessary for regulatory filings.
• Letters of attestation. The MA applicant or CMO should provide written attestations confirming the regulatory purpose of each order, which the API supplier retains as evidence.
• Legal review of patent/SPC landscape. Before accepting an order, the API supplier should conduct (or require the buyer to provide) an analysis of relevant patents and SPCs to assess exposure.

Contracting and Operational Steps for CMOs, CROs and API Suppliers

Robust contractual frameworks are the single most important risk-mitigation tool for any third party relying, directly or derivatively, on the Bolar exemption. The following clause structures and operational controls represent current best practice, though each should be tailored to the specific transaction with qualified legal counsel. Practitioners looking at cross-border IP protection strategies will recognise the importance of jurisdiction-specific drafting.

Key Contract Clauses

• Purpose-restriction clause. “The Services shall be performed solely for the purpose of generating data or material required for the Client’s application for marketing authorisation [MA number / project code] and for no other purpose. The Supplier/CMO/CRO shall not use, retain or distribute any materials or data for commercial exploitation.”
• Patent-risk allocation and indemnity. “The Client warrants that the activities described in this Agreement fall within the scope of the Bolar exemption under Section 11 PatG and Article 10(6) of Directive 2001/83/EC. The Client shall indemnify and hold harmless the Supplier/CMO/CRO against any claims, losses or damages arising from patent or SPC infringement related to the Services, except to the extent caused by the Supplier’s/CMO’s/CRO’s breach of the purpose restriction.”
• Documentation and audit rights. “Each party shall maintain complete records of all activities, quantities and project codes relating to the Services for a minimum of [X] years after patent/SPC expiry. The Client shall have the right to audit the Supplier’s/CMO’s/CRO’s records to verify compliance with the purpose restriction.”
• Termination trigger. “Either party may terminate this Agreement immediately upon written notice if the Bolar exemption is held inapplicable to the Services by a court of competent jurisdiction or if regulatory circumstances render the MA application impracticable.”

Operational Controls

• Physical and administrative segregation. MA-related batches should be manufactured, stored and documented separately from commercial production to prevent commingling and to provide clear evidence of regulatory purpose.
• Labelling. All materials produced under a Bolar-reliant contract should be clearly labelled with the MA project code and the notation “For regulatory use only, not for commercial distribution.”
• Internal compliance training. Personnel involved in Bolar-related projects should receive documented training on the scope and limitations of the exemption.

Red-Flag Checklist for RFPs and New Engagements

• Does the MA applicant have a credible regulatory filing timeline?
• Are requested quantities consistent with regulatory (not commercial) needs?
• Has the patent/SPC landscape been assessed and documented?
• Is there a written purpose-restriction clause in the proposed contract?
• Does the contract include an indemnity and audit provision?
• Can batch-level traceability be maintained throughout the supply chain?

Litigation Risk and Enforcement: What to Expect in Germany in 2026

Germany remains one of Europe’s most active jurisdictions for pharmaceutical patent enforcement. The Düsseldorf, Munich and Mannheim courts hear a disproportionate share of EU patent disputes, and originator companies have historically pursued aggressive injunction strategies against generic entrants and, increasingly, against their supply-chain partners. The relevance of the Bolar exemption in Europe’s busiest patent courts cannot be overstated.

Key enforcement trends and practical considerations for 2026 include:

• Preliminary injunctions. German courts can and do grant preliminary injunctions in patent cases, sometimes ex parte. A CMO, CRO or API supplier that cannot demonstrate a credible Bolar defence supported by contemporaneous documentation may face injunctive relief before it has the opportunity to fully litigate the issue. Early evidence preservation is essential.
• Burden of proof. The party invoking the Bolar exemption bears the burden of proving that the contested activities fall within its scope. This places a premium on documentary evidence, contracts, project codes, batch records, regulatory correspondence, created at the time the activity is performed, not assembled retrospectively for litigation.
• Information and disclosure orders. German procedural law permits courts to order disclosure of documents and records. Originators may seek inspection of manufacturing records, supply agreements and regulatory filings to test whether the alleged Bolar activities are genuine.
• Post-EU Pharma Package alignment. Early indications suggest that German courts will give significant weight to the EU Pharma Package’s clarified Bolar provisions when interpreting Section 11 PatG. However, until leading appellate decisions are handed down, some interpretive uncertainty will persist, particularly regarding the outer boundaries of third-party coverage.

Firms engaged in generic or biosimilar development should conduct regular intellectual property audits and ensure that their Bolar compliance framework is litigation-ready at all times.

Practical Compliance Roadmap: Six Steps for In-House Legal and Regulatory Teams

1. Map the patent and SPC landscape. Identify all relevant patents and SPCs covering the target compound, formulation, process and indication in Germany and relevant EU markets. Assign responsibility to IP counsel; update quarterly.
2. Map the supply chain. Document every third-party entity involved in MA-related activities, API suppliers, CMOs, CROs, analytical laboratories, and assess each entity’s Bolar exposure.
3. Implement contractual controls. Ensure every third-party agreement contains purpose-restriction, indemnity, documentation, audit and termination clauses aligned with the sample provisions described above.
4. Establish documentation and labelling protocols. Create standard operating procedures for MA project-code assignment, batch-level traceability, segregation and labelling. Retain records for the full patent/SPC term plus statute-of-limitations buffer.
5. Engage regulatory authorities proactively. Where appropriate, align filing timelines with patent/SPC expiry dates and maintain a documented regulatory strategy that supports the Bolar narrative.
6. Prepare for litigation. Assemble a litigation-readiness file, including all contractual, documentary and regulatory evidence supporting the Bolar defence, and brief external patent litigation counsel before any enforcement risk materialises.

Conclusion

Understanding what the Bolar exemption is, and what it does not cover, is fundamental for every participant in Germany’s pharmaceutical supply chain in 2026. The EU Pharma Package has advanced harmonisation, but the boundaries of Section 11 PatG coverage for CMOs, CROs and API suppliers remain in flux. Proactive contractual controls, rigorous documentation and litigation-ready evidence management are the pillars of effective Bolar compliance. Companies navigating these complexities can explore further resources through the Global Law Experts lawyer directory to connect with qualified German patent and pharmaceutical law specialists.

Sources

1. German Patent Act (PatG), Section 11
2. Directive 2001/83/EC (Article 10(6)), EUR-Lex
3. European Commission, EU Pharma Package
4. CMS Germany, Guide on Bolar Provisions (Germany)
5. Crowell, EU Pharma Package Bolar Exemption Client Alert
6. Max-Planck Institute, Bolar Exemption and API Supply
7. IBA, Bolar Exemptions and Recent Case Notes
8. GRUR International / Oxford Academic, Bolar and Third-Party Coverage